Investigational drug · Phase 2
BNT165c
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malaria.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "BNT165c"
First trial start
2023
Nov 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNT165c", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malaria
Approved drugs for the same conditions: Malaria · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BNT165c" as an intervention, largest first.
- A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaPivotal-lookingCompleted
BioNTech SEIndustry
NCT06069544 · 163 participants · Start Nov 13, 2023 · Primary completion May 28, 2025
Drug: BNT165c; BNT165d · For: Malaria
Sites: Tempe, Arizona; Baltimore, Maryland; Las Vegas, Nevada · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Malaria
- BNT165dPhase 21 trial
BioNTech SE · Malaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.